US20150132764A1 - Bag3 as biochemical serum and tissue marker - Google Patents

Bag3 as biochemical serum and tissue marker Download PDF

Info

Publication number
US20150132764A1
US20150132764A1 US14/572,445 US201414572445A US2015132764A1 US 20150132764 A1 US20150132764 A1 US 20150132764A1 US 201414572445 A US201414572445 A US 201414572445A US 2015132764 A1 US2015132764 A1 US 2015132764A1
Authority
US
United States
Prior art keywords
bag3
seq
biological sample
rna
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/572,445
Other languages
English (en)
Inventor
Maria Caterina Turco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biouniversa SRL
Original Assignee
Biouniversa SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biouniversa SRL filed Critical Biouniversa SRL
Assigned to BIOUNIVERSA S.R.L. reassignment BIOUNIVERSA S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TURCO, MARIA CATERINA
Publication of US20150132764A1 publication Critical patent/US20150132764A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2527/00—Reactions demanding special reaction conditions
    • C12Q2527/101—Temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Definitions

  • the present invention concerns BAG3 RNA or a fragment thereof for use as biochemical markers in the diagnosis of a pathological state.
  • BAG3 (RefSeq: NP — 004272; Gene ID 9531) is a 74 kDa cytoplasmic protein particularly concentrated in the rough endoplasmic reticulum.
  • BAG3 protein belongs to the family of co-chaperones that interact with the ATPase domain of the heat shock protein HSP70 through the structural domain known as BAG domain (110-124 amino acids).
  • BAG3 contains a WW domain and a proline-rich repeat (PXXP), that can mediate binding to other proteins.
  • bag3 gene expression is constitutive in a few normal cell types, including myocytes, and in several primary tumours or tumour cell lines. Moreover it can be induced by a variety of stressors: indeed stressful stimuli activate the heat shock transcription factor (HSF) 1, that is responsible for the expression of stress-activated genes, including bag3 (Rosati A, Graziano V, De Laurenzi V, Pascale M, Turco M C.
  • HSF heat shock transcription factor
  • BAG3 a multifaceted protein that regulates major cell pathways. Cell Death Dis. 2011; 2: e141). Evidence indicates that BAG3 has a role in sustaining cell survival, by modulating, in either Hsp70-dependent or -independent fashion, the levels or localisation of apoptosis-regulating proteins, such as IKK ⁇ , Bax or BRAF, depending on cell context.
  • BAG3 protein appears to be expressed during cardiomyoblasts differentiation and to sustain myogenin expression. These findings indicate an involvement of BAG3 in late heart development (De Marco M, Turco M C, Rosati A. BAG3 protein is induced during cardiomyoblast differentiation and modulates myogenin expression. Cell Cycle. 2011; 10: 850-852). Moreover, in cardiomyocytes BAG3 has been shown to localize at Z-disc and interact with the actin capping protein, CapZ ⁇ 1, stabilizing myofibril structure and possibly preserving myofibrillar integrity during mechanical stress. BAG3 mutations can impair the Z-disc assembly and increase the sensitivity to stress-induced apoptosis.
  • the present invention concerns BAG3 RNA or a fragment thereof for use as biochemical markers in the diagnosis of a pathological state.
  • said BAG3 RNA is a BAG3 mRNA.
  • said diagnosis is in vitro or ex vivo.
  • a further aspect of the present invention is that the recipient of said diagnosis is a mammalian, preferably a human.
  • BAG-3 RNA or a fragment thereof of the present invention has the advantages of being specific for a pathological state selected from the group consisting of a heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues.
  • said heart disease is selected from: angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
  • the cancer is selected from: pancreatic cancer, bladder cancer and prostate cancer.
  • a further embodiment of the present invention is a kit for the detection and/or quantification of BAG3 gene expression in a biological sample characterized by comprising a couple of single-stranded oligonucleotide primers encompassed by the bag3 nucleotide sequence (SEQ ID NO 18).
  • kit comprise a couple of primers selected from those having a nucleotide sequence included in one of the region from nucleotide 1 to nucleotide 360, from nucleotide 466 to nucleotide 1570 or from nucleotide 1801 to nucleotide 2533 of the bag3 nucleotide sequence.
  • kits comprises a couple of primers selected from those having the following sequences: SEQ ID NO. 1 and SEQ ID NO. 2; SEQ ID NO. 3 and SEQ ID NO. 4; SEQ ID NO. 5 and SEQ ID NO. 6; SEQ ID NO. 7 and SEQ ID NO. 8; SEQ ID NO. 9 and SEQ ID NO. 10.
  • said primers have an annealing temperature between 60 and 75° C., preferably of 72° C.
  • said set of primers is suitable for the detection and/or quantification of BAG3 RNA or a fragment thereof by quantitative real-time RT-PCR.
  • said biological sample is a serum, plasma, urine, saliva or tissue sample.
  • said serum, plasma, urine, saliva or tissue sample is from a mammalian, preferably a human.
  • said kit is specific for the diagnosis of a pathological state selected from the group consisting of a heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues.
  • said heart disease is selected from: angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
  • the cancer is selected from: pancreatic cancer, bladder cancer and prostate cancer.
  • a further embodiment of the present invention is a method for detecting and quantify the levels of BAG3 RNA or a fragment thereof in a biological sample, comprising the steps of:
  • the method of the present invention further comprises the additional step of:
  • said serum, plasma, urine, saliva or tissue sample is from a mammalian, preferably a human.
  • the presence of said BAG3 RNA or of a fragment thereof is associated with a pathological condition.
  • said pathological condition is selected from the group consisting of a heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues.
  • said heart disease is selected from: angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
  • said cancer disease is selected from: pancreatic cancer, bladder cancer and prostate cancer.
  • the invention still further relates to a immunohistochemistry (IHC) kit for the detection of BAG3 protein in a biological sample, wherein said biological sample is preferably a tissue sample, comprising BAG3-specific antibodies and reagents including probes needed for the staining.
  • IHC immunohistochemistry
  • FIG. 1 is a diagrammatic representation of FIG. 1 .
  • FIG. 1A detection of BAG3 protein in supernatants from cultured cardiomyocytes.
  • Human (HCMa) and rat (H9c2) cardiomyocytes at 80% confluency were incubated with or without 10% FBS for 16 hours at 37° C. in a 5% CO 2 atmosphere.
  • Supernatants were dialyzed in a buffer containing 50 mM NaCl and 0.05% IGEPAL, lyophilized, resuspended in 1 ml of RIPA buffer (50 mM Tris HCl pH 7.6, 150 mM sodium chloride, 2 mM sodium orthovanadate, 4 mM EDTA, 10 mM sodium pyrophosphate, 1% NP-40, 0.1% sodium deoxycholate), and analyzed with anti-BAG3 or anti-GAPDH antibodies by western blotting.
  • RIPA buffer 50 mM Tris HCl pH 7.6, 150 mM sodium chloride, 2 mM sodium orthovanadate, 4 mM EDTA, 10 mM sodium pyrophosphate, 1% NP-40, 0.1% sodium deoxycholate
  • FIG. 1B detection of BAG3 protein in exocytic vesicles.
  • Surnatants obtained from H9c2 cells were subjected to sequential centrifugations: (i) 2′000 ⁇ g for 15 min, to remove cells; (ii) 10′000 ⁇ g for 30 min, to remove cellular debris; (iii) 150′000 ⁇ g for 90 min, to pellet exocytic vesicles.
  • the pellet was washed once in PBS at 150′000 ⁇ g for 90 min and analyzed with the anti-BAG3 TOS-2 polyclonal antibody in comparison with a whole-cell lysate by western blot.
  • Rab-4 was analyzed as a marker for exocytic vesicles.
  • GAPDH a cytosolic protein, was analyzed as a control.
  • FIG. 1C Sera from two healthy donors and from two patients affected by chronic heart failure were analyzed with the anti-BAG3 antibody TOS-2 polyclonal antibody in western blotting.
  • FIG. 1D Bands obtained in two patients affected by chronic heart failure were excised from the gel and its identity analyzed by mass spectrometry using the program MASCOT.
  • FIG. 2 is a diagrammatic representation of FIG. 1 .
  • FIG. 2A detection of BAG3 protein in sera from CHF patients.
  • BAG3 recombinant protein and whole-cell lysate from HCMa cells were analyzed by western blotting with serum (1:40) obtained from a patient with heart failure. Analysis with serum from a healthy donor was performed as negative control.
  • FIG. 2B detection of anti-BAG3 antibodies by ELISA test. Sera from 50 CHF patients (with ejection fraction ⁇ 60%) were compared with sera from 50 healthy donor for the presence of anti-BAG3 antibodies in a specific ELISA test. Results are plotted as arbitrary units.
  • FIG. 2C ROC analysis of ELISA test results. Cut-off on 0.083 A.U. results in 74% sensitivity and 68% specificity.
  • FIG. 3 is a diagrammatic representation of FIG. 3 .
  • FIG. 3A Confocal microscopy analysis of direct fluorescence performed for detection of rBAG3-FITC binding to HCMa cells (a, b, c) and J774 A1 cells (d, e, f, g, h, i).
  • BAG3 recombinant protein and purified BSA albumin from bovine serum purchased from SIGMA
  • BAG3 recombinant protein and purified BSA were conjugated to FITC using the FluoroTag FITC Conjugation Kit purchased from SIGMA following the manufacturer instructions.
  • ⁇ -integrin was analyzed as control (a, d, g).
  • Cells were analyzed by a Zeiss LSM confocal microscope. Merged images are shown in c, f
  • FIG. 3B BAG3 binds macrophages. J774 A1 macrophages (1 ⁇ 10 6 cells/ml) were incubated with different concentration of Fitc-BAG3 protein (7, 14 and 70 nm). FITC-BSA (70 nM) was used as a negative control (grey). Cells fluorescence was analyzed by flow cytometry.
  • FIG. 3C panel a—Analysis of Cox-2 and iNOS levels in J774 A1 macrophages incubated with BAG3. J774 A1 cells at 80% confluency were incubated with control medium, BSA, LPS or rBAG3, for 20 hours. Polymixin was added where indicated to verify that the effects of E. coli -derived rBAG3 were independent from the presence of contaminating endotoxin. Cox-2 and iNOS expression were analyzed in cell lysates by Western blotting.
  • FIG. 3C panel b Analysis of nitrite release from J774 A1 macrophages incubated with BAG3. J774 A1 cells at 80% confluency were incubated with control medium, BSA, LPS or rBAG3 for 24 hours. 100 ⁇ l of supernatants from each sample were incubated with 100 ⁇ l of Griess reagent; the optical density at 550 nm (OD550) was measured with a Beckman DU62 spectrophotometer. Nitrite concentration was evaluated by comparing the OD550 of the sample with that of a standard curve of sodium nitrite.
  • FIG. 3C panel c Analysis of IL-6 release from J774 A1 macrophages incubated with BAG3. J774 A1 cells at 80% confluency macrophages were incubated with control medium, BSA, LPS or recombinant BAG3 for 5 hours. BAG3 peptides (peptide 1, peptide 2, peptide 3, peptide 4 or scrambled peptide) 625 nM were added where indicated to verify their ability to block BAG3 activity. IL-6 production was measured in cell culture medium using an ELISA test. IL-6 concentration was evaluated by comparing the OD of the sample with that of a standard curve of recombinant IL-6.
  • FIG. 4 is a diagrammatic representation of FIG. 4 .
  • FIG. 4A is a diagrammatic representation of FIG. 4A .
  • FIG. 4B is a diagrammatic representation of FIG. 4A .
  • FIG. 4C is a diagrammatic representation of FIG. 4A .
  • FIG. 5 is a diagrammatic representation of FIG. 5 .
  • FIG. 6 is a diagrammatic representation of FIG. 6 .
  • FIG. 7 is a diagrammatic representation of FIG. 7 .
  • FIG. 7A is a diagrammatic representation of FIG. 7A .
  • bag3 mRNA relative expression evaluated by qRT-PCR is shown in a graph where values are reported as mean+S.D.
  • the blue line represents the median value calculated.
  • FIG. 7B is a diagrammatic representation of FIG. 7A .
  • FIG. 8 is a diagrammatic representation of FIG. 8 .
  • FIG. 8A is a diagrammatic representation of FIG. 8A .
  • Pancreatic cancer cell lines (PSN1, Capan-1, AsPC-1, PANC-1 and MIA PaCa-2) were treated with different concentrations of gemcitabine as indicated in the graph. After 48 hours, apoptotic cell death was analyzed. Graph depicts mean percentage of Sub G0/G1 cells ( ⁇ S.D.). Data are representative of three independent experiments.
  • FIG. 8B is a diagrammatic representation of FIG. 8A .
  • FIG. 8C is a diagrammatic representation of FIG. 8C .
  • MIA PaCa-2 and PANC-1 cell lines were treated with 2 ⁇ M gemcitabine (GEM) for the indicated times BAG3 protein expression levels were monitored by western blot.
  • GEM gemcitabine
  • FIG. 8D is a diagrammatic representation of FIG. 8D .
  • bag3 mRNA levels were analyzed by RT-PCR; graph depicts relative bag3 mRNA levels ( ⁇ S.D.) and data are representative of three independent experiments.
  • FIG. 8E is a diagrammatic representation of FIG. 8A .
  • MIA PaCa-2 and PANC-1 cell lines were transfected with BAG3 siRNA or a non-targeted siRNA (NTsiRNA) for 72 hours and then treated with 2 ⁇ M gemcitabine (GEM) for 24 h.
  • BAG3 levels were analyzed by western blot and GAPDH levels were detected to monitor equal loading conditions.
  • FIG. 8F is a diagrammatic representation of FIG. 8F .
  • MIA PaCa-2 and PANC-1 cells were transfected as described above and treated with 2 ⁇ M gemcitabine (GEM) for 24 h or 48 h. Apoptotic cell death was analyzed as described. Graph depicts mean percentage of Sub G0/G1 cells ( ⁇ S.D.). Data are representative of three independent experiments.
  • FIG. 9 is a diagrammatic representation of FIG. 9 .
  • FIG. 9A Detection of BAG3 specific immuno-complexes by ELISA test. Sera from 55 pancreatic adenocarcinoma patients were compared with sera from 51 healthy donors for the presence of BAG3 specific immune-complexes in a specific ELISA test. Results are plotted as arbitrary units ⁇ S. E.
  • FIG. 9B ROC analysis of ELISA test results. Cut-off on 0.183 A.U. results in 65% sensitivity and 78% specificity.
  • FIG. 10 is a diagrammatic representation of FIG. 10 .
  • Bag3 score was calculated in each sample, as relative expression levels using the comparative method, after normalizing for the expression of the endogenous GAPDH.
  • the present invention concerns BAG3 RNA or a fragment thereof for use as biochemical markers in the diagnosis of a pathological state.
  • BAG3 RNA fragment in the present invention we refer to fragments of 150-300 nucleotides.
  • diagnosis in the present invention we refer to medical diagnosis (often simply termed diagnosis) that refers to the process of attempting to determine or identify a possible disease or disorder.
  • diagnosis of the present invention encompasses also the early diagnosis.
  • early diagnosis we refer to the capacity of the test to discriminate a pathological state before specific or aspecific symptoms.
  • Anti-BAG3 antibodies have now been advantageously detected in serum. Until now such antibodies had never been found in serum either in physiological or pathological condition.
  • the detection of anti-BAG3 antibodies in serum has the advantage of being a rapid and non-invasive technique be exploited for diagnostic, early diagnosis and prognostic purposes, risk stratification, as a tool for the identification and for monitoring therapies.
  • a further advantage of the detection of antibodies is that a very small amount of serum is required for the detection.
  • soluble BAG3 protein can also be detected in the serum of patients suffering from some pathologies, but the amount of serum requested for the detection of the soluble protein is much higher than that required for the detection of antibodies.
  • soluble BAG3 protein levels can be much lower than those of antibodies and/or that, respect to soluble BAG3 protein, antibodies can be detectable in earlier phases of specific pathologies and/or can more efficiently predict risk of complications or monitor the effects of therapies.
  • serum is intended the component of blood that is neither a blood cell nor a clotting factor; it is the blood plasma with the fibrinogens removed.
  • Serum includes all proteins not used in blood clotting (coagulation) and all the electrolytes, antibodies, antigens, hormones, and any exogenous substances.
  • plasma is intended the straw-colored/pale-yellow liquid component of blood that normally holds the blood cells in whole blood in suspension. It contains clotting factors, such as fibrinogens.
  • the invention provides the use of anti-BAG3 antibodies as biochemical markers, wherein said anti-BAG3 antibodies are bound to soluble BAG3 to form immune complexes.
  • Anti-BAG3 antibodies either free or bound to soluble BAG3 to form immune complexes have advantageously been now detected in a biological and may be used as a marker in the diagnosis of a pathological condition.
  • the detection of such antibodies and/or immune complexes in a biological sample also has the advantage of being a rapid and non-invasive technique for diagnostic and/or prognostic purposes.
  • immune complex or protein/antibody complex is intended the integral binding of an antibody to a soluble antigen, the bound antigen acting as a specific epitope, bound to an antibody is referred to as a singular immune complex.
  • Immune complexes have the same advantages seen as for the detection of antibodies, since a very small amount of serum is required also for the detection of the immune complex.
  • the amount of serum required for the detection of soluble BAG3 is much higher also than that required for the detection of the protein/antibody (immune) complexes.
  • Immune complexes as well as free antibodies can be detectable in earlier phases of specific pathologies and can more efficiently predict risk of complications or monitor the effects of therapies.
  • a still further embodiment of the invention is the use of anti-BAG3 antibodies or said immune complexes (formed by anti-BAG3 antibodies bound to soluble BAG3) as biological markers of a pathological state, wherein said pathological state is a heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues.
  • said heart disease is selected from the group consisting of: angina pectoris, pre-infarction angina, ischemia, myocardial infarction, heart failure, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
  • a further embodiment of the present invention is method for detecting the presence of an anti-BAG3 antibody or an anti-BAG3 antibody bound to soluble BAG3 to form an immune complex in a biological sample, comprising the steps of:
  • the method according to the present invention has the advantage of allowing to detect significant differences between anti-BAG3 antibodies and/or BAG3/antibodies complexes between healthy individuals and patients affected by BAG3-involving pathologies.
  • the proposed assay method allows a statistically significant separation of the group of cardiac patients from the group of healthy people. It can also stratify such patients with heart disease in subgroups of patients at increased risk (heart failure, HF).
  • the invention relates to a method for detecting the presence of an anti-BAG3 antibody in a biological sample or an anti-BAG3 antibody bound to soluble BAG3 to form an immune complex, further comprising the step of:
  • the method according to the present invention is a method wherein said determination step b. is performed by an ELISA test.
  • the method according to the present invention has the advantage of allowing the rapid and non-invasive detection of the biological markers allowing the evaluation of pathologies, risks for diseases and/or their complications, and monitoring of therapies.
  • the invention relates to a detection method wherein the presence of said anti-BAG3 antibody or said anti-BAG3 antibody bound to soluble BAG3 to form an immune complex is associated with a pathological condition.
  • said pathological condition is chosen from the group consisting of heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues.
  • said heart disease is selected from the group consisting of: angina pectoris, pre-infarction angina, myocardial infarction, ischemia, heart failure, acute coronary disease, acute heart failure, chronic heart failure or iatrogenic heart disease.
  • the invention further relates to an ELISA kit for the detection of anti-BAG3 antibodies or anti-BAG3 antibodies bound to soluble BAG3 to form an immune complexes in a biological sample.
  • the ELISA kit according to the present invention comprises a BAG3 recombinant protein for capturing anti-BAG3 antibodies or BAG3-specific mouse monoclonal antibodies AC-1, AC-2, AC-3, AC-4 and AC-5, for capturing soluble BAG3 and antibodies able to recognize human immunoglobulins.
  • Such antibodies can be enzyme-linked antibodies able to recognize human immunoglobulins.
  • the invention also relates to a kit for the detection of BAG3-associated antibodies in a biological sample and is performed by ELISA with BAG3-specific mouse monoclonal antibodies AC-1, AC-2, AC-3, AC-4 and AC-5, capturing soluble BAG3 and enzyme-linked antibodies for the detection able to recognize human immunoglobulins.
  • the invention still further relates to a immunohistochemistry (IHC) kit for the detection of BAG3 protein in a biological sample, wherein said biological sample is preferably a tissue sample.
  • Tissue samples can be biopsies, frozen tissues, paraffin embedded tissues.
  • the IHC kit according to the present invention comprises BAG3-specific antibodies and reagents including probes needed for the staining.
  • Said BAG3-specific antibodies can be mouse monoclonal antibodies AC-1, AC-2 and AC-3 and/or enzyme-linked antibodies for the detection able to recognize mouse immunoglobulins.
  • the IHC kit advantageously allows to reveal BAG3 protein in 100% of pancreatic carcinoma tissue samples from patients that undergo pancreas resection and is expressed in most bladder carcinoma samples.
  • BAG3 protein can be revealed with the kit for BAG3 detection by IHC also in normal pancreas tissue in Langerhans islets while other normal tissues result negative (such for example normal urocystis ). BAG3 positivity can be also observed in synovial fibroblasts and inflammatory infiltrates in rheumatoid arthritis tissue samples.
  • the BAG3 IHC kit allows the identification of the prognosis of PDAC patients. It was seen that the intensity of BAG3 expression identified by IHC, correlates with patients' survival. Therefore it can be used for both prognosis and for making a choice of therapy.
  • a further embodiment of the present invention is BAG3 RNA or a fragment thereof for use as biochemical markers in the diagnosis of a pathological state.
  • said BAG3 RNA is a BAG3 mRNA.
  • the BAG3 RNA corresponds to the BAG3 nucleotide sequence of SEQ ID N. 18 (Reference: NCBI PubMed, XM 055575.1 Homo sapiens BCL2-associated athanogene 3 (BAG3) mRNA).
  • BAG3 RNA or a fragment thereof has now been advantageously detected in serum, plasma, urine, saliva or tissue sample. Until now such BAG3 RNA had never been found in the above mentioned biological sample either in physiological or pathological condition.
  • the detection of BAG3 RNA or a fragment thereof in serum, and in different biological sample, such as plasma, urine, saliva or tissue has the advantage of being a rapid and non-invasive technique be exploited for diagnostic, early diagnosis and prognostic purposes, risk stratification, as a tool for the identification and for monitoring therapies.
  • a further advantage of the detection and the quantification of BAG3 RNA or a fragment thereof is that a very small amount of sample is required for the detection.
  • said diagnosis is in vitro or ex vivo.
  • a further aspect of the present invention is that the recipient of said diagnosis is a mammalian, preferably a human.
  • BAG-3 RNA or of a fragment thereof of the present invention has the advantages of being specific for a pathological state selected from the group consisting of a heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues.
  • said heart disease is selected from: angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
  • the cancer is selected from: pancreatic cancer, bladder cancer and prostate cancer.
  • a further embodiment of the present invention is a kit for the detection and/or quantification of BAG3 gene expression in a biological sample characterized by comprising a couple of single-stranded oligonucleotide primers encompassed by the bag3 nucleotide sequence (SEQ ID NO 18).
  • kit comprise a couple of primers selected from those having a nucleotide sequence included in one of the region from nucleotide 1 to nucleotide 360, from nucleotide 466 to nucleotide 1570 or from nucleotide 1801 to nucleotide 2533 of the bag3 nucleotide sequence.
  • kits comprises a couple of primers selected from those having the following sequences: SEQ ID NO. 1 and SEQ ID NO. 2; SEQ ID NO. 3 and SEQ ID NO. 4; SEQ ID NO. 5 and SEQ ID NO. 6; SEQ ID NO. 7 and SEQ ID NO. 8; SEQ ID NO. 9 and SEQ ID NO. 10.
  • the RT-PCR kit for bag3 mRNA detection in a biological sample allows to correlate the levels of bag3 gene expression with patients' survival and can be used for prognosis and for choice of therapy.
  • said biological sample is a serum, plasma, saliva, urine and tissue sample.
  • said primers have an annealing temperature between 60 and 75° C., more preferably of 72° C.
  • said set of primers is suitable for the detection and/or quantification of BAG3 RNA or a fragment thereof by quantitative real-time RT-PCR.
  • said biological sample is a serum, plasma, urine, saliva or tissue sample.
  • said serum, plasma, urine, saliva or tissue sample is from a mammalian, preferably a human.
  • said kit is specific for the diagnosis of a pathological state selected from the group consisting of a heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues.
  • said heart disease is selected from: angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
  • the cancer is selected from: pancreatic cancer, bladder cancer and prostate cancer.
  • a further embodiment of the present invention is a method for detecting and quantify the levels of BAG3 RNA or a fragment thereof in a biological sample, comprising the steps of:
  • RNA levels in a biological sample there are different methods for detecting or quantify the RNA levels in a biological sample: Northern blot, RT-PCR, qRT-PCR, DNA-microarray.
  • a real-time polymerase chain reaction also called quantitative real time polymerase chain reaction (qPCR) or kinetic polymerase chain reaction is a laboratory technique based on the polymerase chain reaction (PCR), which is used to amplify and simultaneously quantify a targeted DNA molecule.
  • qPCR quantitative real time polymerase chain reaction
  • PCR polymerase chain reaction
  • Real Time-PCR enables both detection and quantification.
  • the quantity can be either an absolute number of copies or a relative amount when normalized to DNA input or additional normalizing genes.
  • the procedure follows the general principle of polymerase chain reaction; its key feature is that the amplified DNA is detected as the reaction progresses in real time. This is a new approach compared to standard PCR, where the product of the reaction is detected at its end.
  • Two common methods for the detection of products in real-time PCR are: (1) non-specific fluorescent dyes that intercalate with any double-stranded DNA, and (2) sequence-specific DNA probes consisting of oligonucleotides that are labelled with a fluorescent reporter which permits detection only after hybridization of the probe with its complementary DNA target.
  • mRNA messenger RNA
  • non-coding RNA in cells, tissues or biological samples.
  • Real-time reverse-transcription PCR is often denoted as: qRT-PCR.
  • RT-PCR commonly denotes reverse transcription polymerase chain reaction.
  • the method of the present invention further comprises the additional step of:
  • said serum, plasma, urine, saliva or tissue sample is from a mammalian, preferably a human.
  • the presence of said BAG3 RNA or a fragment thereof is associated with a pathological condition.
  • said pathological condition is selected from the group consisting of a heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues.
  • said heart disease is selected from: angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
  • said cancer disease is selected from: pancreatic cancer, bladder cancer and prostate cancer.
  • a still further aspect of the invention is represented by anti-BAG3 monoclonal antibodies, their fragments, and peptides corresponding to specific aminoacidic sequences of BAG3 protein that are able to block macrophage activation and can therefore be used for therapy of inflammatory, oncologic or other diseases involving macrophage activation. See in particular FIG. 3 and Table I.
  • This invention relates to the use of BAG3-specific mouse monoclonal antibodies AC-1, AC-2 and AC-3 or same modified as F(ab), F(ab′)2, F(ab) or humanized; or peptides comprising sequences as follows:
  • PEP 1 DRDPLPPGWEIKIDPQ (SEQ ID NO. 12)
  • PEP2 SSPKSVATEERAAPS (SEQ ID NO. 13)
  • PEP3 DKGKKNAGNAEDPHT (SEQ ID NO. 14)
  • PEP4 NPSSMTDTPGNPAAP as molecules able to bind and/or block soluble BAG3 effects.
  • Cardiomyocytes are known to release protective factors in mounting a response against stressful agents. Since stress-induced proteins, such as Hsp70, Hp27, Hsp90 and others, although exerting an intracellular activity, can also be secreted in response to stress, BAG3 release by cardiomyocytes was analyzed in stressful conditions. For this purpose, we analyzed the effect of serum deprivation-induced stress in cultured human primary cardiomyocytes or the rat cardiomyocyte cell line H9c2. As shown in FIG. 1 , we could detect BAG3 protein in the supernatants of cardiomyocytes exposed to serum deprivation for 16 h ( FIG. 1A ).
  • the human BAG 3 protein has the amino acid sequence according to SEQ ID NO:15.
  • BAG3 release by cardiomyocytes We addressed the functional significance of BAG3 release by cardiomyocytes. We excluded that the protein could be involved in an autocrine pathway, because it did not apparently bind to the cardiomyocyte surface, as we assessed in experiments using fluorescein isothiocyanate (FITC)-conjugated BAG3 ( FIG. 3A ). Therefore we investigated whether BAG3 could interact with blood cells. Indeed, we found that FITC-BAG3 bound to macrophages of the cell line J774 ( FIG. 3B ). BAG3 binding to macrophages was specifically impaired by competing BAG3 peptides or by BAG3-sequestering F(ab′)2 fragments from anti-BAG3 monoclonal antibodies (Table I).
  • J774 cells were incubated with 14 nM FITC-BAG3 protein and with 625 nM of BAG3 peptides (peptide 1, peptide 2, peptide 3, peptide 4 or scrambled peptide) or with 420 nM of F(ab′)2 fragments from anti-BAG3 monoclonal and polyclonal antibodies (mouse monoclonal AC1, AC2 and rabbit polyclonal TOS2).
  • F(ab′)2 fragments from mouse IgG or F(ab′)2 fragments from rabbit IgG were used as a negative control.
  • BAG3 binding to macrophages
  • iNOS inducible nitric oxide synthase
  • Cox cyclooxygenase
  • FIG. 3C panel a the levels of those enzymes were enhanced in BAG3-treated macrophages.
  • BAG3 induced the release of nitrite and interleukin (IL)-6 ( FIG. 3C panels b and c) confirming that macrophages were activated in response to their binding to the protein.
  • IL interleukin
  • BAG3-specific mouse monoclonal antibodies AC-1, AC-2 and AC-3 and/or others or same modified as F(ab), F(ab′)2, F(ab) or humanized; or peptides comprising sequences PEP 1 to 4 and/or others are molecules able to bind and/or block soluble BAG3 effects to be used for therapy of inflammatory, oncologic or other diseases involving macrophage activation.
  • IHC immunohistochemistry
  • This kit revealed BAG3 expression in all the 346 (100%) PDAC biopsies that we analyzed.
  • BAG3 staining revealed a moderate positivity of Langerhans islets, while normal pancreatic ducts and pancreatic acinar cells had no BAG3 expression. This was true in both normal pancreas and non-neoplastic pancreatic tissue adjacent to the tumour mass. BAG3 staining was observed predominantly in the cytoplasm of tumor cells. The intensity of staining of BAG3 was variable as was the number of positive cancer cells.
  • the first-line chemotherapy for treatment of pancreatic cancer is gemcitabine.
  • BAG3 protein in response to therapy, we analyzed the effect of BAG3 down-modulation in human PDAC cells.
  • Silencing of BAG3 enhanced cell apoptosis in response to the drug ( FIG. 8 ).
  • bag3 primers that detect BAG3 expression by quantitative real-time RT-PCR.
  • RT-PCR kit containing specific primers for bag3 mRNA detection and quantification.
  • RNA was obtained from urine and bag3 RNA levels were measured by RT-PCR. Bag3 score was calculated in each sample, as relative expression levels using the comparative method, after normalizing for the expression of the endogenous GAPDH. In the reported table bag3 was compared between two groups having displaying different PCA3 score.
  • PCA3 is a prostate specific non-coding mRNA that is significantly overexpressed in prostate cancer tissue.
  • PCA3 score is calculated using quantitative polymerase chain reaction (qPCR) technology; in particular PCA3 and PSA (Prostate Specific Antigen) mRNA molecules are amplified and the PCA3 Score is calculated as equal to 1000 ⁇ [mRNA PCA3]/[mRNA PSA]. (ref: Bussemakers M J, van Bokhoven A, Verhaegh G W, Smit F P, Karthaus H F, Schalken J A et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9).
  • qPCR quantitative polymerase chain reaction
  • PCA3 Score ⁇ 35 A patient with a PCA3 Score ⁇ 35 has a high probability of having PCA and repeat biopsy is advisable. If the outcome is negative (PCA3 Score ⁇ 35), the patient has a lower probability of having PCA and repeat biopsy might be delayed with active surveillance/follow-up of the patient.
  • bag3 RNA determination in urine samples can represent a novel tool for risk assessment to develop prostate cancer.
  • HCMa Human Cardiac Myocytes-adult were purchased from Sciencell Research Laboratories (San Diego, Calif.) and grown in Cardiac Myocyte Medium (CMM, FBS 5%, Cardiac Myocyte Growth Supplement 1%, penicillin/streptomycin solution 1%) (Sciencell Research Laboratories, San Diego, Calif.). All experiments were performed on low-passage cell cultures.
  • Embryonic rat cardiomyoblasts (line H9c2) was purchased from the American Type Culture Collection (ATCC, Manassas, Va., USA) and grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 ⁇ g/mL streptomycin.
  • DMEM Dulbecco's Modified Eagle's Medium
  • FBS fetal bovine serum
  • J774A.1 murine monocyte macrophage cell line (ATCC, Manassas, Va., USA), was grown in DMEM supplemented with 10% fetal bovine serum (FBS), 25 mM HEPES, 2 mM glutamine, 100 u/mL penicillin and 100 ⁇ g/mL streptomycin.
  • pancreatic cancer cell lines (MIA PaCa-2, AsPC-1, PSN1, Capan-1 and PANC-1) were received from the American Type Culture Collection (ATCC; Manassas, Va.) cell bank.
  • MIA PaCa-2 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) and supplemented with 10% FBS and 2.5% horse serum.
  • AsPC-1 and PSN1 cells were grown in RPMI-1640 Medium supplemented with 10% FBS.
  • Capan-1 were cultured in RPMI-1640 containing 20% FBS while PANC-1 were cultured in DMEM supplemented with 10% FBS.
  • Sera were diluted 1:40 with dissociation buffer (PBS with 1.5% BSA and 0.2 M glycine-acetate pH 2.5) to a 500 ⁇ l final volume and incubated for 20 min at room temperature.
  • the sera were then pipetted into the sample reservoir of Microcon centrifugal filter device, YM-100 (100,000 MW cut-off; Millipore, Billerica, Mass., USA) and centrifuged at 14,100 rpm for 20 min at room temperature.
  • the sample reservoir was then separated from the flow through, placed inverted into a second tube and centrifuged at 5,000 rpm for 3 min at room temperature.
  • the collected solution containing the antibody dissociated was adjusted to pH 7.0 with 1 M Tris buffer, pH 9.0.
  • the retentate volume was reconstituted to the initial volume (500 ⁇ l) with dilution buffer (PBS with 1.5% BSA and 0.1% Tween-20). 14
  • the dissociated antibodies were diluted 1:200 in TBST containing 5% bovine serum albumin overnight at 4° C.
  • Cells were harvested and lysed in a buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl, 0.1% Triton (TNN buffer) supplemented with a protease inhibitors cocktail (1 mM phenylmethylsulfonyl fluoride, 1 mg/ml pepstatin A, 2 mg/ml aprotinin) by 3 cycles of freezing and thawing. Soluble proteins were collected after a centrifugation at 10,000 g for 15 min and their amount was determined by Bradford assay (Bio-Rad, Hercules, Calif.).
  • Protein bands were excised and gel pieces were subsequently washed with MilliQ Water and Acetonitrile and the proteins were digested in situ as described in Shevchenko protocol. Briefly, gel slices were reduced in 1,4-dithiothreitol (10 mM) and alkylated with iodoacetamide (50 mM), then washed and rehydrated in trypsin solution (12 ng/ ⁇ L) on ice for 1 h. After the addition of 30 ⁇ L ammonium bicarbonate (10 mM, pH 7.5), samples were digested overnight at 25° C. 5 ⁇ L of the obtained peptide mixture were injected onto a nano Acquity LC system (Waters Corp. Manchester, United Kingdom).
  • the peptides were separated on a 1.7 ⁇ m BEH C-18 column (Waters Corp. Manchester, United Kingdom) at a flow rate of 200 nl/min.
  • the gradient (Solution A: 0.1% formic acid, solution B: 0.1% formic acid, 100% ACN) started at 5% and ended at 50% B after 55 min.
  • MS and MS/MS data were acquired using a Q-TOF Premier mass spectrometer (Waters Corp., Micromass, Manchester, United Kingdom). Doubly and triply charged peptide-ions were automatically chosen by the MassLynx software and fragmented.
  • MS data were automatically processed and peak lists for protein identifications by database searches were generated by the ProteinLynx software. Database searches were carried out with MASCOT server using the SwissProt protein database.
  • the SwissProt human database (405506 sequences; 146166984 residues) was searched allowing 1 missed cleavage, carbamidomethyl(C) as fixed modification.
  • the peptide tolerance was set to 60 ppm and the MS/MS tolerance to 0.8 Da.
  • Serum-free medium of H9c2 was cleared of cells and large debris by serial centrifugation at 4° C. (2000 ⁇ g for 15 min, 10,000 ⁇ g for 30 min). After each of the first two centrifugations, pellets are discarded, and the supernatant is kept for the next step. The final supernatant is then ultracentrifuged at 150,000 ⁇ g for 90 min at 4° C. (with a SW50.1 rotor, and an Optima L-90K Ultracentrifuge, Beckman Coulter) to pellet exosomes. The pellet is washed in PBS to eliminate contaminating proteins and centrifuged one last time at 150,000 ⁇ g for 90 min at 4° C.
  • rBAG3 binding—J774 A.1 cells were blocked with 2% FBS+0.1% NaN3 in PBS for 15 min on ice and incubated (2.5 ⁇ 105/100 ⁇ l) with different concentration of FITC-rBAG3 protein (7, 14 and 70 nm) or FITC-BSA (70 nM) in PBS containing 2% FBS+0.1% NaN3 for 30 min at 4° C. in the dark. After washing with PBS, the cells were resuspended in PBS+2% FBS+0.1% NaN3 and analyzed with a FACScan (BD Biosciences) flow cytometer.
  • FACScan BD Biosciences
  • IL6 was measured in supernatant of J774 A.1 cells (5 ⁇ 10 4 /in 96-well microplates) treated with LPS (10 ng/ml) or with rBAG3 (14 nM) or BSA (14 nM) for 10 or 20 hours in absence or presence of polymyxin B sulfate (5 ⁇ g/ml). After treatment 50 ⁇ L of cell culture medium were collected and analyzed in triplicate with a mouse IL6 Kit (eBioscience).
  • Images were acquired in sequential scan mode by using the same acquisitions parameters (laser intensities, gain photomultipliers, pinhole aperture, objective 63 ⁇ , zoom 2) when comparing experimental and control material.
  • brightness and contrast of images were adjusted by taking care to leave a light cellular fluorescence background for visual appreciation of the lowest fluorescence intensity features and to help comparison among the different experimental groups.
  • Final figures were assembled using Adobe Photoshop 7 and Adobe Illustrator 10. Leica Q9 Confocal Software and ImageJ were used for data analysis.
  • NUNC Maxisorp 96 well ELISA plates were coated with recombinant BAG3 protein 1 ⁇ g/ml (50 ⁇ l/well) in PBS, pH 7 and incubated overnight at 4° C. Plates were washed 2 times with washing buffer (PBS+0.05% Tween-20), and then blocked (150 ⁇ l/well) for one hour at room temperature with 0.5% fish gelatin in PBS. Following blocking, the plates were washed 2 times with washing buffer and sera were diluted 1:70 with 0.5% fish gelatin in washing buffer and then applied (50 ⁇ l/well) in triplicate and incubated at room temperature for two hour. The plates were then washed 6 times with washing buffer.
  • washing buffer PBS+0.05% Tween-20
  • Anti-human IgG (H+L) antibody (Sigma Aldrich) was diluted 1:20,000 with 0.5% fish gelatin in washing buffer, added at 50 ⁇ l/well and incubated at 4° C. for 30 minutes. After incubation, the plates were washed 6 times, developed with TMB (50 ⁇ l/well) (eBioscience), the reaction stopped with 4.5 M sulfuric acid (25 ⁇ l/well) and the plates were analyzed spectrophotometrically at 450 nm.
  • Nitrite content (NO 2 ⁇ ), a stable metabolite of NO released by cells in the culture supernatant, was measured in J774 A.1 cells (5 ⁇ 104/in 96-well microplates) treated with LPS (10 ng/ml) or with rBAG3 (7, 14 and 28 nM) or BSA (28 nM) for 24 hours in absence or presence of polymyxin B sulfate (Sigma-Aldrich, St. Louis, Mo., USA) 5 ⁇ g/ml. NO 2 ⁇ amounts were measured by Griess reaction.
  • Anti-human IgG (H+L) antibody (Sigma Aldrich) was diluted 1:20,000 with 0.5% fish gelatin in washing buffer, added at 50 ⁇ l/well and incubated at 4° C. for 30 minutes. After incubation, the plates were washed 6 times, developed with TMB (50 ⁇ l/well) (eBioscience), the reaction stopped with 4.5 M sulfuric acid (25 ⁇ l/well) and the plates were analyzed spectrophotometrically at 450 nm.
  • Immunohistochemistry protocol included: deparaffination in xylene, re-hydration through descending concentrations of alcohol up to pure water, non-enzymatic antigen retrieval in citrate buffer, pH 6.0, for 30 minutes at 95° C., and endogenous peroxidase quenching with H2O2 in methanol for 20 minutes. After rinsing with PBS, the samples were blocked with 5% normal horse serum in 0.1% PBS/BSA. To detect BAG3, samples were incubated for 1 hour at room temperature with BAG3 monoclonal antibody AC-1, AC-2 or AC-3 at the concentration of 3 microg/ml.
  • RNA concentration and purity were validated by NanoDrop Spectrophotometer (Thermo Fisher, Waltham, Mass., USA).
  • RNA was reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit according to the manufacturer's instructions (Applied Biosystems, Applera, Foster City, Calif., USA). Quantitative real-time PCR assay was used to assess the differential expression of BAG3 in tumor tissue samples.
  • Primers for the human bag3 gene were synthesized by Primm srl (Milano, Italy) (forward primer: (SEQ ID NO:16) CCT GTT AGC TGT GGT TG; reverse primer: (SEQ ID NO:17) AAC ATA CAG ATA TTC CTA TGG C).
  • RNA samples 1 ml of urine collected after prostatic massage and stabilized with RNA protector buffer were transferred in 15 ml falcon tube, and mixed with 2 ml of Trizol Reagent® and 1 ml of chloroform. Samples were centrifuged for 15 minutes at 4° C., 8000 rpm. Aqueous phase was transferred in a new falcon tube and 1 ml of pure ethanol was added. Sample was mixed and transferred (in 4 steps) on RNAeasy qiagen column, then supplier protocol suitable for RNA purification was followed. RNA was eluted in 15 ⁇ l of elution buffer. 12 ⁇ l of eluted RNA were used for the Reverse transcription reaction performed in a final volume of 20 ⁇ l. (Quantitect reverse transcription kit, Qiagen). 2 ⁇ l of synthesized cDNA were used for Real Time PCR screening, on Light Cycler 480 Roche instrument.
  • Bag3 primers were: fw 5′-CAGGAGCAGCACGCCACTCC-3′ (SEQ ID NO:16); rev 5′-TGGTCCAACTGGGCCTGGCT-3′(SEQ ID NO:17).
  • GAPDH mRNA was measured to normalize measured bag3 RNA values with primers: fw 5′-AGCCTCCCGCTTCGCTCTCT-3′ (SEQ ID NO: 19); rev 5′-CCAGGCGCCCAATACGACCA-3′ (SEQ ID NO: 20).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
US14/572,445 2012-06-19 2014-12-16 Bag3 as biochemical serum and tissue marker Abandoned US20150132764A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12172531.1 2012-06-19
EP12172531.1A EP2676966A1 (en) 2012-06-19 2012-06-19 BAG3 as biochemical serum and tissue marker
PCT/EP2013/061971 WO2013189775A1 (en) 2012-06-19 2013-06-11 Bag3 as biochemical serum and tissue marker

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/061971 Continuation WO2013189775A1 (en) 2012-06-19 2013-06-11 Bag3 as biochemical serum and tissue marker

Publications (1)

Publication Number Publication Date
US20150132764A1 true US20150132764A1 (en) 2015-05-14

Family

ID=48607259

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/572,654 Active 2034-03-20 US10359433B2 (en) 2012-06-19 2014-12-16 BAG3 as biochemical serum and tissue marker
US14/572,445 Abandoned US20150132764A1 (en) 2012-06-19 2014-12-16 Bag3 as biochemical serum and tissue marker

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/572,654 Active 2034-03-20 US10359433B2 (en) 2012-06-19 2014-12-16 BAG3 as biochemical serum and tissue marker

Country Status (12)

Country Link
US (2) US10359433B2 (enExample)
EP (3) EP2676966A1 (enExample)
JP (2) JP2015521475A (enExample)
KR (2) KR102150903B1 (enExample)
CN (2) CN104507965B (enExample)
AU (2) AU2013279604B2 (enExample)
BR (2) BR112014031957A2 (enExample)
CA (2) CA2876922C (enExample)
ES (1) ES2795981T3 (enExample)
IN (2) IN2014DN10562A (enExample)
PL (1) PL2861618T3 (enExample)
WO (2) WO2013189778A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130403A1 (it) 2013-03-18 2014-09-19 Biouniversa Srl Anticorpi anti-bag3 per uso terapeutico
CN105021825B (zh) * 2015-07-09 2016-08-17 陈勇 一种检测胰腺癌相关多肽dap44的elisa试剂盒
CN105769900A (zh) * 2016-03-22 2016-07-20 山西大学 Bag3基因在制备抗膀胱癌药物中的应用
IT201600069391A1 (it) * 2016-07-04 2016-10-04 Univ Degli Studi Di Salerno Uso della proteina bag3 e suoi frammenti peptidici per il controllo dell’omeostasi vascolare
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
US11940450B2 (en) 2021-03-16 2024-03-26 University Of Connecticut Biomarker panel for non-invasive diagnosis of congenital renal dysfunction
CN113862361B (zh) * 2021-10-25 2023-08-15 中山大学孙逸仙纪念医院 一种诊断和治疗膀胱癌的分子标志物hsf1及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073623A1 (en) * 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652223A (en) * 1994-03-14 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA encoding CAI resistance proteins and uses thereof
CA2379264A1 (en) * 1999-07-09 2001-01-18 The Burnham Institute A method for determining the prognosis of cancer patients by measuring levels of bag expression
JP4424987B2 (ja) * 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
US20090047689A1 (en) * 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
WO2011044927A1 (en) * 2009-10-12 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the diagnosis or prognosis of an advanced heart failure
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
GB201017520D0 (en) * 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073623A1 (en) * 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Bustin et al., J. Biomol. Tech. vol. 15, no. 3, pages 155-166, 2004. *
Ellen Jensen., The anatomical Record, 295: 1-3, published online November 2011. *
Liao et al., FEBS LETTER, vol. 503, pages 151-157, 2001. *
Staibano et al, Tumor Biology (2010) 31: 461-469 *
Thronton et al., Biochemistry and Molecular biology education, volume 39, no. 2 pages145-154, 2011. *
Zhang et al., Oncology Reports, vol. 27, pages 109-113, January 2012 *
Zong et al. Genes Dev. vol. 15, no. 12, pages 1481-1486, 2001. *

Also Published As

Publication number Publication date
KR20150036111A (ko) 2015-04-07
EP2861618B1 (en) 2020-03-11
JP2015521475A (ja) 2015-07-30
CA2876922A1 (en) 2013-12-27
EP2861754A1 (en) 2015-04-22
AU2013279604A1 (en) 2014-12-18
CN104507965B (zh) 2019-04-26
ES2795981T3 (es) 2020-11-25
EP2676966A1 (en) 2013-12-25
JP6654432B2 (ja) 2020-02-26
PL2861618T3 (pl) 2020-09-21
AU2013279604B2 (en) 2018-03-29
CN104619861A (zh) 2015-05-13
JP2015529633A (ja) 2015-10-08
CA2876872A1 (en) 2013-12-27
KR102150903B1 (ko) 2020-09-03
US10359433B2 (en) 2019-07-23
BR112014031957A2 (pt) 2017-08-01
IN2014DN10561A (enExample) 2015-08-28
BR112014031958A2 (pt) 2017-08-01
CN104507965A (zh) 2015-04-08
US20150147767A1 (en) 2015-05-28
KR20150036102A (ko) 2015-04-07
WO2013189775A1 (en) 2013-12-27
CA2876922C (en) 2022-09-20
AU2013279601A1 (en) 2015-01-15
EP2861618A1 (en) 2015-04-22
WO2013189778A1 (en) 2013-12-27
IN2014DN10562A (enExample) 2015-08-28

Similar Documents

Publication Publication Date Title
Cooley et al. Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis
US20150132764A1 (en) Bag3 as biochemical serum and tissue marker
EP2207037B1 (en) Method for detection of cancer
CN106461681B (zh) 用于诊断血管疾病的生物标志物及其用途
Riau et al. Calcium-binding S100 protein expression in pterygium
EP2421994B1 (en) Bin1 as a prognostic marker in cardiovascular disease
EP1937831B1 (en) Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis
US20130197514A1 (en) Use of imp3 as a prognostic marker for cancer
AU2012271293B2 (en) Biomarkers for epithelial cancer diagnosis and treatment
Artuyants et al. The tumour-derived extracellular vesicle proteome varies by endometrial cancer histology and is confounded by an obesogenic environment
Monsivais Integration of Nuclear Receptor Actions and Inflammatory Pathways in Endometriosis
JP2009542191A (ja) 診断のための生体分子
WO2006129717A1 (ja) 膵癌検出用腫瘍マーカー及びそれを用いた膵癌検出用キット
WO2008093083A2 (en) Prognostic markers for hpv-related cancer

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOUNIVERSA S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TURCO, MARIA CATERINA;REEL/FRAME:035089/0126

Effective date: 20141211

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION